Bioabsorbable scaffolds for patients with diabetes mellitus

Methods and results: 180 patients were included in study and randomized into 2 groups. 82 patients were included in group I, who were implanted bioabsorbable scaffolds ABSORB, while 98 patients in group II, who were implanted drug eluting stents with Evrolimus. Inclusion criteria: primary coronary lesions, stable angina pectoris II – III functional class (CCS), myocardial ischemia, confirmation of stress test, diabetes mellitus in anamnesis, stenosis of mid and distal segments of major coronary arteries ≥70% according to angiography, absence of CABG and PCI in anamnesis. OCT was carried out after implantation after 12 and 18 months.
During hospitalization, the ratio of cumulative MACE were 3.5% in group I and 2.94% in group II (p>0.05), but the survival was 100% in both groups. Long term results were studied in 76 patients from group I and in 82 patients from group II. After 12 months, survival was still 100% in both groups. The ratio of non fatal MI was 4.8% and 3.8% respectively (p>0.05). The ratio of restenosis and re-intervention on the target lesion (TLR) was 0 and 2.04% respectively in group I and II (p>0.05). After 18 months, survival was still 100% in both groups. The ratio of restenosis and re-intervention on the target lesion (TLR) was 0 and 5.1% respectively in group I and II (p=0.034). CONCLUSION: in patients suffering fromd diabetes Mellitus, bioabsorbable scaffolds showed be the high efficiency of the ratio of restenosis and TLR that can be recommended as an alternative strategy.